MGNX MACROGENICS INC
Price Chart
Executive Summary
MacroGenics reported Q1 2026 revenue of $20.8M (up 57% YoY) and net loss of $36.8M, essentially in line with EPS consensus of -$0.57 (actual -$0.58). More importantly, the company announced a manufacturing divestiture and ZYNYZ royalty monetization expected to provide up to $202.5M in non-dilutive capital, extending cash runway through 2028 and reducing near-term financing risk.
Actionable Insight
The business transformation (manufacturing sale + royalty monetization) removes near-term financing overhang and positions MGNX for pipeline catalysts in mid-2026. Traders should watch for MGC026 Phase 1 data in mid-2026, which could be a major inflection point. The stock may re-rate on reduced dilution risk and extended runway.
Key Facts
- Revenue grew 57% YoY to $20.8M driven by contract manufacturing and royalty revenue
- Net loss narrowed to $36.8M from $41.0M in Q1 2025
- EPS of -$0.58 vs consensus -$0.57 (in line)
- Manufacturing operations divestiture to Bora Pharmaceuticals for $122.5M upfront
- Expanded ZYNYZ royalty monetization with Sagard: $60M received plus up to $20M milestone
- Cash runway extended through 2028, up from late 2027 prior guidance
- ADC pipeline on track for multiple data readouts in mid-2026 (MGC026, MGC028, lorigerlimab)
- Lorigerlimab showed 25% objective response rate in CCGC; ovarian cancer program halted
Financial Impact
Manufacturing divestiture and royalty monetization provide up to $202.5M in non-dilutive capital, significantly reducing dilution risk and extending cash runway through 2028.
Risk Factors
- Manufacturing divestiture closing conditions (expected Q3 2026) - transaction risk
- Pipeline data readouts are binary events - clinical failure could erase value
- Partial clinical hold on lorigerlimab LINNET study remains unresolved
- Sagard milestone payment dependent on ZYNYZ 2026 sales performance
Market Snapshot
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001125345-26-000040 |
| Document: mgnx-20260513.htm | 0001125345-26-000040 |
| Document: 0001125345-26-000040-index-headers.html | 0001125345-26-000040 |
| Document: 0001125345-26-000040-index.html | 0001125345-26-000040 |
| Document: 0001125345-26-000040.txt | 0001125345-26-000040 |
| 8-K Data (Synthetic) | 0001125345-26-000040 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
1d ago
|
Institutional Cluster
| $4.01 awaiting T+5 | awaiting T+5 | — | $3.96 (−1.25%) |
|
Jun 11, 2026
2d ago
|
Institutional Cluster
| $3.87 awaiting T+5 | awaiting T+5 | — | $3.96 (+2.33%) |
|
May 13, 2026
4w ago
|
8-K
| $4.16 $4.24 | ▲ +1.92% | ▲ +2.64% | $3.96 (−4.81%) |
|
May 12, 2026
4w ago
|
8-K
| $3.52 $4.35 | ▲ +23.58% | ▲ +23.50% | $3.96 (+12.50%) |
|
May 11, 2026
4w ago
|
Press Release
| $3.52 $4.35 | ▲ +23.58% | ▲ +23.50% | $3.96 (+12.50%) |
|
Apr 8, 2026
9w ago
|
8-K
| $3.44 $3.41 | ▼ −0.87% | ▼ −4.06% | $3.96 (+15.12%) |
|
Apr 8, 2026
9w ago
|
Press Release
| $3.44 $3.41 | ▼ −0.87% | ▼ −4.06% | $3.96 (+15.12%) |
|
Apr 8, 2026
9w ago
|
DEFA14A
| $3.44 $3.41 | ▼ −0.87% | ▼ −4.06% | $3.96 (+15.12%) |
|
Feb 28, 2026
15w ago
|
Institutional Cluster
| $1.94 $2.36 | ▲ +21.65% | ▲ +22.86% | $3.96 (+104.12%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access